Type of Assessment:
BRCA1 haploinsufficiency impairs iron metabolism to promote chrysotile-induced mesothelioma via ferroptosis-resistance
Cancer Science 2022 December 21 [Link] Yaguang Luo, Shinya Akatsuka, Yashiro Motooka, Yingyi Kong, Hao Zheng, Tomoji Mashimo, Tatsuhiko Imaoka, Shinya Toyokuni Abstract Malignant mesothelioma (MM) is still a social burden associated with asbestos exposure. Local iron accumulation thereby represents the major pathogenesis, followed by oxidative DNA strand breaks and genomic alterations in the mesothelium.…
Read MoreIdentification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning
Frontiers in Endocrinology 2022 November 29 [Link] Yingqi Xiao, Wei Huang, Li Zhang, Hongwei Wang Abstract Background: Glycolysis-related genes as prognostic markers in malignant pleural mesothelioma (MPM) is still unclear. We hope to explore the relationship between glycolytic pathway genes and MPM prognosis by constructing prognostic risk models through bioinformatics and machine learning. Methods: The…
Read MoreNR4A3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid/microcystic morphology
Genes, Chromosomes, and Cancer 2022 December 16 [Link] Abbas Agaimy, Luka Brcic, Laurence M Briski, Yin P Hung, Michael Michal, Michal Michal, G Petur Nielsen, Robert Stoehr, Andrew E Rosenberg Abstract A focal adenomatoid-microcystic pattern is not uncommon in peritoneal mesothelioma, but tumors composed almost exclusively of this pattern are distinctly rare and have not…
Read MoreMultimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach
Translational Lung Cancer Research 2022 November [Link] Laura V Klotz, Hans Hoffmann, Rajiv Shah, Florian Eichhorn, Christiane Gruenewald, Elena L Bulut, Raffaella Griffo, Thomas Muley, Petros Christopoulos, Philip Baum, Peter Huber, Seyer Safi, Marc Kriegsmann, Michael Thomas, Helge Bischoff, Hauke Winter, Martin E Eichhorn Abstract Background: The exact role and type of surgery for malignant…
Read MoreCDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
Cancers 2022 November 30 [Link] Rita Terenziani, Maricla Galetti, Silvia La Monica, Claudia Fumarola, Silvia Zoppi, Roberta Alfieri, Graziana Digiacomo, Andrea Cavazzoni, Delia Cavallo, Massimo Corradi, Marcello Tiseo, Pier Giorgio Petronini, Mara Bonelli Abstract Background: The loss of the CDKN2A/ARF (cyclin-dependent kinase inhibitor 2A/alternative reading frame) gene is the most common alteration in malignant pleural…
Read MorePotential Roles of Exosomes in the Development and Detection of Malignant Mesothelioma: An Update
International Journal of Molecular Sciences 2022 December 6 [Link] Phillip Munson, Arti Shukla Abstract Malignant mesothelioma (MM) is a devastating cancer of mesothelial cells, caused by asbestos exposure. Limited knowledge regarding the detection of asbestos exposure and the early diagnosis of MM, as well as a lack of successful treatment options for this deadly cancer,…
Read MoreExtensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury
Annals of Surgical Oncology 2022 December 10 [Link] Lukas F Liesenfeld, Eva Quiring, Mohammed Al-Saeedi, Christian Nusshag, Markus W Büchler, Martin Schneider Abstract Background: Cisplatin (CDDP)-containing hyperthermic intraperitoneal chemotherapy (HIPEC) is frequently applied in selected patients with peritoneal malignancies derived from ovarian cancer, gastric cancer, and primary peritoneal mesothelioma. HIPEC with CDDP increases perioperative morbidity,…
Read MoreIdentification of a new potential plasmatic biomarker panel for the diagnosis of malignant pleural mesothelioma
La Medicina del Lavoro 2022 December 7 [Link] Luca Ferrari, Simona Iodice, Laura Cantone, Barbara Dallari, Laura Dioni, Lorenzo Bordini, Alessandro Palleschi, Carolina Mensi, Angela Cecilia Pesatori Abstract Background: Malignant pleural mesothelioma (MPM) is a rare highly aggressive tumor strongly associated with asbestos exposure and characterized by poor prognosis. Currently, diagnosis is based on invasive…
Read MoreThe STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model
Frontiers in Immunology 2022 November 18 [Link] Peter T Graham, Anna K Nowak, Scott M J Cornwall, Irma Larma, Delia J Nelson Abstract We assessed the murine Stimulator of Interferon Genes (STING) agonist, DMXAA, for anti-mesothelioma potential using the AE17-sOVA model that expresses ovalbumin (OVA) as a neo tumor antigen. Dose response experiments alongside testing…
Read MoreA Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Clinical Cancer Research 2022 December 5 [Link] Hyun-Sung Lee, Hee-Jin Jang, Maheshwari Ramineni, Daniel Y Wang, Daniela Ramos, Jong Min Choi, Taylor Splawn, Monica Espinoza, Michelle Almarez, Leandria Hosey, Eunji Jo, Susan G Hilsenbeck, Christopher I Amos, R Taylor Ripley, Bryan M Burt Abstract Purpose: We report the results of a phase 2, randomized, window-of-opportunity…
Read More